|
Variable
|
Combined
|
Non-progressors
|
AKIN III
|
P
|
|---|
| |
n = 77
|
n = 52
|
n = 25
| |
|---|
|
Age, years
|
65.3 (1.6)
|
63.8 (2.2)
|
68.2 (1.9)
|
0.13
|
|
Gender, % male
|
42.8%
|
36.5%
|
56.0%
|
0.14
|
|
Race, n (%)
| | | | |
|
African American
|
44 (57.1%)
|
29 (55.6%)
|
15 (60.0%)
|
0.63
|
|
Caucasian
|
23 (29.9%)
|
15 (28.8%)
|
8 (32.0%)
|
0.92
|
|
Hispanic
|
10 (13.0%)
|
8 (15.4%)
|
2 (8.0%)
|
0.48
|
|
Comorbidities, n (%)
| | | | |
|
CKD
|
24 (31.0%)
|
17 (32.7%)
|
7 (28.0%)
|
0.80
|
|
Hypertension
|
60 (78.0%)
|
41 (78.8%)
|
19 (76.0%)
|
0.78
|
|
CHF
|
25 (33.0%)
|
15 (29.0%)
|
10 (40.0%)
|
0.44
|
|
DM
|
35 (44.0%)
|
22 (41.5%)
|
13 (52.0%)
|
0.47
|
|
Nephrotoxic exposure, n (%)
| | | | |
|
NSAIDS
|
8 (10.0)%
|
6 (2.0%)
|
2 (1.0%)
|
1.00
|
|
Aminoglycosides
|
1 (1.0%)
|
0 (0.0%)
|
1 (0.4%)
|
0.63
|
|
Amphotericin
|
2 (3.0%)
|
2 (4.0%)
|
0 (0.0%)
|
1.00
|
|
Contrast
|
21 (27.0%)
|
15 (28.8%)
|
6 (23.1%)
|
0.79
|
|
Post-cardiac surgery
|
9 (11.7%)
|
6 (11.5%)
|
3 (12.0%)
|
1.00
|
|
Sepsis
|
15 (19.5%)
|
12 (23.1%)
|
3 (12.0%)
|
0.36
|
|
Clinical Data
| | | | |
|
Baseline eGFR, ml/minute/1.73m2
|
68.6 (4.1)
|
60.0 (8.8)
|
73.3 (4.2)
|
0.15
|
|
Baseline UFR (ml/hr)
|
74.6 (11.6)
|
95.7 (16.3)
|
29.7 (4.2)
|
0.001
|
|
Furosemide-naïve, n (%)
|
29 (37.7%)
|
23 (44.2%)
|
6 (24.0%)
|
0.13
|
|
Urine cast score)
|
2.3 (0.13)
|
2.1 (0.16)
|
2.7 (0.23)
|
0.05
|
|
FeNa above 1%, n (%)a
|
14 (18.0%)
|
10 (19.2%)
|
4 (16.0%)
|
1.00
|
|
CV SOFA score
|
1.16 (0.3)
|
1.05 (0.2)
|
1.5 (0.4)
|
0.37
|
|
APACHE II score
|
17.8 (1.11)
|
16.5 (1.2)
|
21.6 (2.5)
|
0.08
|
|
AKIN stage at enrollment, n (%)
| | | | |
|
AKIN I
|
41 (53.2%)
|
34 (65.4%)
|
7 (28.0%)
|
0.003
|
|
AKIN II
|
36 (46.7%)
|
18 (34.6%)
|
18 (72.0%)
|
0.003
|
|
Outcomes, n (%)
| | | | |
|
Death
|
16 (20.7%)
|
7 (13.4%)
|
9 (36.0%)
|
0.04
|
|
AKIN stage III
|
25 (32.4%)
|
N/A
|
25 (100%)
|
N/A
|
|
RRT
|
11 (14.2%)
|
N/A
|
11 (44.0%)
|
N/A
|
|
Death/AKIN III
|
32 (41.5%)
|
7 (13.4%)
|
25 (100.0%)
|
0.001
|
- Data are presented as mean ± standard error unless otherwise indicated. CKD, chronic kidney disease; CHF, congestive heart failure; DM, diabetes mellitus; NSAIDs, non-steroidal anti-inflammatory drugs; eGFR, estimated glomerular filtration rate; UFR, urinary flow rate; CV SOFA, Cardiovascular Sequential Organ Failure Assessment; APACHE, Acute Physiology and Chronic Health Evaluation; AKIN, Acute Kidney Injury Network; FeNa, fractional excretion of sodium; RRT, renal replacement therapy; RPP, renal perfusion pressure; n, number of patients; N/A, not applicable. aFeNa not assessed in 29 patients because the George Washington University Urine Sediment Score was already ≥2 at the time of assessment.
